NEW YORK (AP) – Chinese drugmaker Simcere Pharmaceutical Group said that its rheumatoid arthritis drug Iremod received marketing approval from China’s State Food and Drug Administration.
Iremod is intended to treat active rheumatoid arthritis. Simcere’s other products include the cancer treatments Endu and Sinofuan, along with branded generic drugs and over-the-counter products.
Date: August 25, 2011
Source: Associated Press
Filed Under: Drug Discovery